Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NASDAQ:LGND NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.75+0.3%$8.93$7.21▼$20.46$2.02B0.723.43 million shs5.93 million shsANIPANI Pharmaceuticals$84.50+1.5%$80.58$62.60▼$99.50$1.92B0.44303,365 shs780,585 shsLGNDLigand Pharmaceuticals$303.59+2.6%$238.60$111.71▼$305.71$6.08B1.17398,062 shs1.25 million shsUTHRUnited Therapeutics$542.66-0.1%$561.23$272.12▼$609.35$23.07B0.57546,633 shs1.02 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.29%+5.23%+10.42%-5.46%-50.31%ANIPANI Pharmaceuticals+1.46%+6.30%+3.35%+16.04%+28.21%LGNDLigand Pharmaceuticals+2.59%+10.44%+28.70%+55.30%+162.35%UTHRUnited Therapeutics-0.13%+1.13%-4.92%+3.79%+89.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.75+0.3%$8.93$7.21▼$20.46$2.02B0.723.43 million shs5.93 million shsANIPANI Pharmaceuticals$84.50+1.5%$80.58$62.60▼$99.50$1.92B0.44303,365 shs780,585 shsLGNDLigand Pharmaceuticals$303.59+2.6%$238.60$111.71▼$305.71$6.08B1.17398,062 shs1.25 million shsUTHRUnited Therapeutics$542.66-0.1%$561.23$272.12▼$609.35$23.07B0.57546,633 shs1.02 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.29%+5.23%+10.42%-5.46%-50.31%ANIPANI Pharmaceuticals+1.46%+6.30%+3.35%+16.04%+28.21%LGNDLigand Pharmaceuticals+2.59%+10.44%+28.70%+55.30%+162.35%UTHRUnited Therapeutics-0.13%+1.13%-4.92%+3.79%+89.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.33Hold$19.67124.89% UpsideANIPANI Pharmaceuticals 2.75Moderate Buy$107.3327.02% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$257.71-15.11% DownsideUTHRUnited Therapeutics 2.85Moderate Buy$619.4214.14% UpsideCurrent Analyst Ratings BreakdownLatest LGND, ADMA, ANIP, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)6/18/2026ADMAADMA Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/11/2026UTHRUnited Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)6/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Outperform$21.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$21.006/1/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/26/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/15/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/14/2026ANIPANI Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$252.00 ➝ $262.00(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M3.97$0.66 per share13.33$2.01 per share4.35ANIPANI Pharmaceuticals$883.37M2.18$10.08 per share8.38$24.03 per share3.52LGNDLigand Pharmaceuticals$268.09M22.69$8.05 per share37.69$51.68 per share5.87UTHRUnited Therapeutics$3.18B7.24$32.95 per share16.47$164.81 per share3.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6812.869.30N/A32.43%39.98%28.08%8/5/2026 (Estimated)ANIPANI Pharmaceuticals$78.34M$3.9521.399.76N/A9.98%27.51%10.02%8/14/2026 (Estimated)LGNDLigand Pharmaceuticals$124.45M$7.3741.1936.673.3155.95%16.19%11.13%8/6/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0920.0317.561.7940.62%19.24%17.25%7/29/2026 (Estimated)Latest LGND, ADMA, ANIP, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28$2.05+$0.77$1.28$207.63 million$237.46 million5/7/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93ANIPANI Pharmaceuticals1.063.122.52LGNDLigand Pharmaceuticals0.4521.2820.95UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%LGNDLigand Pharmaceuticals91.28%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%ANIPANI Pharmaceuticals8.10%LGNDLigand Pharmaceuticals7.00%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableANIPANI Pharmaceuticals60022.75 million20.90 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableLGND, ADMA, ANIP, and UTHR HeadlinesRecent News About These CompaniesSG Americas Securities LLC Cuts Stock Position in United Therapeutics Corporation $UTHRJune 27 at 4:32 AM | marketbeat.comAssenagon Asset Management S.A. Purchases 22,555 Shares of United Therapeutics Corporation $UTHRJune 27 at 3:12 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $5,212,555.00 in StockJune 26 at 5:51 AM | insidertrades.comLouisiana State Employees Retirement System Buys Shares of 12,500 United Therapeutics Corporation $UTHRJune 26 at 5:19 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,108,530.00 in StockJune 25 at 5:51 AM | insidertrades.comJames Edgemond Sells 8,750 Shares of United Therapeutics (NASDAQ:UTHR) StockJune 25 at 4:53 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) CFO Sells $4,708,812.50 in StockJune 24 at 4:51 AM | insidertrades.comQ1 earnings outperformers: United Therapeutics (NASDAQ:UTHR) and the rest of the therapeutics stocksJune 23, 2026 | msn.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells $4,708,812.50 in StockJune 23, 2026 | marketbeat.comHsbc Holdings PLC Has $70.05 Million Stock Position in United Therapeutics Corporation $UTHRJune 23, 2026 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells $5,401,500.00 in StockJune 23, 2026 | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares of StockJune 22, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Stake Raised by TobamJune 20, 2026 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of StockJune 19, 2026 | insidertrades.comWick Capital Partners LLC Takes $75.86 Million Position in United Therapeutics Corporation $UTHRJune 19, 2026 | marketbeat.comSeven Fleet Capital Management LP Acquires New Stake in United Therapeutics Corporation $UTHRJune 19, 2026 | marketbeat.comPacer Advisors Inc. Sells 97,199 Shares of United Therapeutics Corporation $UTHRJune 19, 2026 | marketbeat.comInspire Investing LLC Has $5.88 Million Stock Holdings in United Therapeutics Corporation $UTHRJune 18, 2026 | marketbeat.comEvolve Private Wealth LLC Takes $6.83 Million Position in United Therapeutics Corporation $UTHRJune 18, 2026 | marketbeat.comElmind Capital LP Buys Shares of 11,000 United Therapeutics Corporation $UTHRJune 18, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Holdings Increased by Eversept Partners LPJune 18, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026LGND, ADMA, ANIP, and UTHR Company DescriptionsADMA Biologics NASDAQ:ADMA$8.74 +0.03 (+0.29%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$8.72 -0.02 (-0.29%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$84.50 +1.22 (+1.46%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$84.46 -0.04 (-0.05%) As of 06/26/2026 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Ligand Pharmaceuticals NASDAQ:LGND$303.59 +7.67 (+2.59%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$284.00 -19.59 (-6.45%) As of 06/26/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.United Therapeutics NASDAQ:UTHR$542.66 -0.73 (-0.13%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$542.50 -0.16 (-0.03%) As of 06/26/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
